Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent
activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this
study will evaluate survival rates and toxicities in patients with poor risk stage III NSCLC.